Dermata Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing the company's first net sales, a widening net loss, and a private placement completed in August 2026.
Key Highlights
- First recorded revenue: Net sales of $74,137 were reported for both the three and nine months ended September 30, 2026, compared to $0 in the same periods of 2025, according to the filing.
- Net loss widened: The company reported a net loss of $2,821,400 for the three months ended September 30, 2026, versus $1,691,989 in the prior-year quarter.
- Nine-month net loss: For the nine months ended September 30, 2026, the net loss was $7,636,169, compared to $5,696,669 for the same period in 2025.
- August 2026 PIPE completed: The company issued Common Stock and warrants in an August 2026 private placement, netting $3,197,427 after issuance costs, per the stockholders' equity statement.
- Cash position: Cash and cash equivalents stood at $4,822,357 as of September 30, 2026, down from $7,521,978 at December 31, 2025.
- Accumulated deficit: The accumulated deficit reached $80,870,065 as of September 30, 2026, up from $73,233,896 at December 31, 2025.
- Shares outstanding: 4,930,207 shares of Common Stock were issued and outstanding as of November 9, 2026, up from 2,660,110 at December 31, 2025.
Dermata Therapeutics Reports First Product Sales and Increased Operating Expenses in Q3 2026
According to the filing, Dermata Therapeutics, Inc. (NASDAQ:DRMA) generated its first net sales of $74,137 during the three and nine months ended September 30, 2026, producing a gross profit of $40,129 after cost of sales of $34,008. The company had reported no revenue in the corresponding periods of 2025. Total operating expenses for the nine months ended September 30, 2026 were $7,838,577, compared to $5,873,205 in the prior-year period, driven primarily by selling, general and administrative expenses of $7,098,996 versus $3,469,842 in the nine months ended September 30, 2025.
Research and development expenses declined to $739,581 for the nine months ended September 30, 2026, from $2,403,363 in the same period of 2025, the filing disclosed. Interest income for the nine-month period was $162,279, compared to $176,536 in 2025. The company's net loss per share, basic and diluted, was $(0.55) for Q3 2026 on a weighted-average share count of 5,119,529, versus $(1.65) per share on 1,026,457 weighted-average shares in Q3 2025.
The balance sheet as of September 30, 2026 showed total assets of $6,635,491, including inventories of $825,279 (which were $0 at December 31, 2025), and total liabilities of $2,729,565. Total stockholders' equity was $3,905,926, down from $6,223,380 at year-end 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was $7,551,023. During Q1 2026, the company also raised approximately $1,994,051, net of issuance costs, through at-the-market stock sales, and exercised pre-funded warrants covering 537,750 shares.
What Was Disclosed
Dermata Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting its first product revenue, a nine-month net loss of $7,636,169, an August 2026 private placement netting $3,197,427, and cash of $4,822,357 at period end.



Please wait processing your request...